Novo Nordisk (NVO) is a buy due to the FDA approval of its oral weight loss drug, Wegovy, which is expected to be a significant growth driver.
Source Post
New viral weight loss drug wegovy turned into pill form! Oral wegovy pills just got FDA approved and can re...
Dec 24, 2025
The creator discusses the FDA approval of Novo Nordisk's oral weight loss drug, Wegovy, highlighting its potential market impact and comparing it to the injectable form. The creator expresses a positive outlook on the stock (NVO) due to this development, while also noting potential concerns about long-term research for such drugs.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
NVObuy opened Dec 24, 2025
-4.26%